Table 3 Immunomodulatory therapies among all PRESS participants at any time during the course of the study
Treatments (n = 301) | Baseline only | Any time during study* |
|---|---|---|
Mycophenolate mofetil, n (%) | 121 (40.2) | 207 (68.8) |
 Dose (mg/day), mean (±SD) | 1876.9 (±737.0) | 2045.4 (±644.5) |
Methotrexate, n (%) | 42 (14.0) | 64 (21.3) |
 Dose (mg/week), mean (±SD) | 14.9 (±6.8) | 15.8 (±5.6) |
Cyclophosphamide, n (%) | 6 (2.0) | 15 (5.0) |
 Dose (mg/day), mean (±SD) | 33.6 (±14.4) | 44.4 (±27.0) |
D-penicillamine, n (%) | 5 (1.7) | 8 (2.7) |
 Dose (mg/day), mean (±SD) | 650.0 (±285.0) | 686.9 (±246.6) |
Hydroxychloroquine, n (%) | 39 (13.0) | 53 (17.6) |
 Dose (mg/day), mean (±SD) | 319.4 (±103.7) | 317.8 (±97.1) |
Azathioprine, n (%) | 5 (1.7) | 7 (2.3) |
 Dose (mg/day), mean (±SD) | 115.0 (±41.8) | 110.7 (±34.9) |
Any immunomodulatory therapy, n (%) | 190 (63.1) | 260 (86.4) |
Autologous hematopoietic stem cell transplantation, n (%) | 1 (0.3) | 4 (1.3) |
Prednisone, n (%) | 90 (29.9) | 127 (42.2) |
 Dose (mg/day), mean (±SD) | 9.9 (±7.9) | 9.2 (±5.2) |